# Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

Study · id `cardio:ct-nct03081598` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03081598](<https://clinicaltrials.gov/study/NCT03081598>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03081598

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 104 participants.

## Technical summary

Registry record NCT03081598. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-29 (actual); primary completion 2018-09-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 104 participants (enrolled count; ClinicalTrials.gov record NCT03081598, source copy `cardio:ctgov-nct03081598-2020-12-08`, retrieved 2026-10-26)
- Started: 2017-05-29 (actual) (ClinicalTrials.gov record NCT03081598, source copy `cardio:ctgov-nct03081598-2020-12-08`, retrieved 2026-10-26)
- Primary completion: 2018-09-06 (actual) (ClinicalTrials.gov record NCT03081598, source copy `cardio:ctgov-nct03081598-2020-12-08`, retrieved 2026-10-26)
- Completion: 2018-09-06 (actual) (ClinicalTrials.gov record NCT03081598, source copy `cardio:ctgov-nct03081598-2020-12-08`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT03081598, source copy `cardio:ctgov-nct03081598-2020-12-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03081598-2020-12-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
- Condition: Type 2 Diabetes Mellitus
- Condition: Metabolic Syndrome
- Intervention (Drug): PBI-4050
- Intervention (Other): Placebo
- Lead sponsor: Liminal BioSciences Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: cf38827ec1269181e9a20bc26e6cb16f148f5675cb29f252f5ac3a6f2f9c4bde
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
